GEOVAX LABS INC (GOVX) Stock Price & Overview
NASDAQ:GOVX • US3736787058
Current stock price
The current stock price of GOVX is 1.29 USD. Today GOVX is down by -3.73%. In the past month the price decreased by -21.64%. In the past year, price increased by 61.54%.
GOVX Key Statistics
- Market Cap
- 2.864M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -35.25
- Dividend Yield
- N/A
GOVX Stock Performance
GOVX Stock Chart
GOVX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to GOVX. When comparing the yearly performance of all stocks, GOVX turns out to be only a medium performer in the overall market: it outperformed 43.24% of all stocks.
GOVX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to GOVX. While GOVX seems to be doing ok healthwise, there are quite some concerns on its profitability.
GOVX Earnings
GOVX Forecast & Estimates
10 analysts have analysed GOVX and the average price target is 258.19 USD. This implies a price increase of 19914.57% is expected in the next year compared to the current price of 1.29.
For the next year, analysts expect an EPS growth of 75.98% and a revenue growth -54.79% for GOVX
GOVX Groups
Sector & Classification
GOVX Financial Highlights
Over the last trailing twelve months GOVX reported a non-GAAP Earnings per Share(EPS) of -35.25. The EPS increased by 92.57% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -375.99% | ||
| ROE | -515.76% | ||
| Debt/Equity | 0 |
GOVX Ownership
GOVX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 371.899B | ||
| AMGN | AMGEN INC | 15.23 | 189.187B | ||
| GILD | GILEAD SCIENCES INC | 15.83 | 174.329B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.84 | 113.007B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.05 | 79.873B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.06 | 45.013B | ||
| INSM | INSMED INC | N/A | 33.111B | ||
| NTRA | NATERA INC | N/A | 30.421B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.133B | ||
| BIIB | BIOGEN INC | 11.14 | 26.264B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.83 | 25.357B | ||
| MRNA | MODERNA INC | N/A | 20.956B | ||
| INCY | INCYTE CORP | 12.62 | 19.441B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GOVX
Company Profile
GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is headquartered in Smyrna, Georgia and currently employs 17 full-time employees. Its lead clinical program is GEO-CM04S1, a COVID-19 vaccine, which is in three phase II clinical trials, being evaluated as a primary vaccine for immunocompromised patients, such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient; a booster vaccine in patients with chronic lymphocytic leukemia (CLL); and a COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology, the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin, having completed a multicenter Phase I/II clinical trial for advanced head and neck cancers. The company is developing GEO-MVA, a vaccine targeting Mpox and smallpox. Its other product candidates include GEO-EM01-Z, GEO-EM01-S, GEO-MM01, GEO-ZM02 and others.
Company Info
IPO: 1994-04-04
GEOVAX LABS INC
1955 Lake Park Drive, Suite 300
Smyrna GEORGIA 30080 US
CEO: David A. Dodd
Employees: 17
Phone: 16783847220
GEOVAX LABS INC / GOVX FAQ
What does GEOVAX LABS INC do?
GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is headquartered in Smyrna, Georgia and currently employs 17 full-time employees. Its lead clinical program is GEO-CM04S1, a COVID-19 vaccine, which is in three phase II clinical trials, being evaluated as a primary vaccine for immunocompromised patients, such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient; a booster vaccine in patients with chronic lymphocytic leukemia (CLL); and a COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology, the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin, having completed a multicenter Phase I/II clinical trial for advanced head and neck cancers. The company is developing GEO-MVA, a vaccine targeting Mpox and smallpox. Its other product candidates include GEO-EM01-Z, GEO-EM01-S, GEO-MM01, GEO-ZM02 and others.
What is the current price of GOVX stock?
The current stock price of GOVX is 1.29 USD. The price decreased by -3.73% in the last trading session.
What is the dividend status of GEOVAX LABS INC?
GOVX does not pay a dividend.
What is the ChartMill technical and fundamental rating of GOVX stock?
GOVX has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting GOVX stock to perform?
10 analysts have analysed GOVX and the average price target is 258.19 USD. This implies a price increase of 19914.57% is expected in the next year compared to the current price of 1.29.
What is the expected growth for GOVX stock?
The Revenue of GEOVAX LABS INC (GOVX) is expected to decline by -54.79% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the Short Interest ratio of GEOVAX LABS INC (GOVX) stock?
The outstanding short interest for GEOVAX LABS INC (GOVX) is 11.4% of its float.